Approval · Notice of Compliance 13402 · 2012
QUETIAPINE TABLETS: Notice of Compliance 13402
Issued June 20, 2012
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 13402
- Date
- June 20, 2012
- Company
- Accord Healthcare IncKirkland, Quebec, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Abbreviated New Drug Submission (ANDS)
- Submission class
- Other
- Therapeutic class
- Antipsychotic Agent
- Canadian reference product
- SEROQUEL (Astrazeneca Canada Inc)
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| QUETIAPINE TABLETS | 02387794 | Marketed |
| QUETIAPINE TABLETS | 02387808 | Marketed |
| QUETIAPINE TABLETS | 02387816 | Marketed |
| QUETIAPINE TABLETS | 02387824 | Marketed |
| QUETIAPINE TABLETS | 02387832 | Marketed |
Medicinal ingredients
- QUETIAPINE FUMARATE 25 MG per TAB
- QUETIAPINE FUMARATE 100 MG per TAB
- QUETIAPINE FUMARATE 150 MG per TAB
- QUETIAPINE FUMARATE 200 MG per TAB
- QUETIAPINE FUMARATE 300 MG per TAB